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Background: Benefits of early nephrology care are well-established, but as many as 40% of U.S. patients with
end-stage renal disease (ESRD) do not see a nephrologist before its onset. Our objective was to evaluate the effect
of proactive, population-based nephrologist oversight (PPNO) on chronic kidney disease (CKD) progression.
Methods: Retrospective control analysis of Kaiser Permanente Hawaii members with CKD using propensity score
matching methods. We matched 2,938 control and case pairs of individuals with stage 3a CKD for the pre-PPNO
period (2001–2004) and post-PPNO period (2005–2008) that were similar in other characteristics: age, gender, and
the presence of diabetes and hypertension. After three years, we classified the stage outcomes for all individuals.
We assessed the PPNO effect across all stages of progression with a χ2- test. We used the z-score test to assess
the proportional differences in progression within a stage.
Results: The progression within the post-PPNO period was less severe and significantly different from the
pre-PPNO period (p = 0.027). Within the stages, there were 2.6% more individuals remaining in 3a in the
post-period (95% confidence interval [CI], 1.5% to 3.8%; P value < 0.00001). Progression from 3a to 3b was 2.2% less
in the post-period (95% [CI], 0.7% to 3.6%; P value = 0.0017), 3a to 4/5 was 0.2% less (95% CI, 0.0% to 0.87%; P
value = 0.26), and 3a to ESRD was 0.24% less (95% CI, 0.0% to 0.66%, P value = 0.10).
Conclusions: Proactive, population-based nephrologist oversight was associated with a statistically significant
decrease in progression. With enabling health information technology, risk stratification and targeted intervention
by collaborative primary and specialty care achieves population-level care improvements. This model may be
applicable to other chronic conditions.Background
In tandem with increasing rates of obesity and diabetes,
the prevalence of chronic kidney disease (CKD) continues
to rise. Recent estimates suggest that 11.5% to 14.5% of
the U.S. adult population has early- to late-stage CKD
[1-3]. Benefits of early nephrology care for CKD are
well-established: slowed progression of disease, better
preparation for renal replacement therapy (RRT), greater
likelihood of outpatient hemodialysis initiation, and
reduced mortality [4-6]. Yet as many as 40% of patients
in the United States do not see a nephrologist before the
onset of end-stage renal disease (ESRD) , and fewer than* Correspondence: marianne.c.turley@kp.org
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reproduction in any medium, provided the or25% have been followed by a nephrologist for at least a
year before end-stage disease [7].
A new model of care providing proactive population-
based nephrologist oversight (PPNO) reduces late refer-
rals and increases the proportion of patients starting
hemodialysis with a mature arteriovenous fistula and as
outpatients [8]. The model consists of risk stratifying a
CKD population and providing unsolicited nephrologist
consultations to primary care physicians regarding indi-
vidual patients, enabled by an integrated electronic
health record (EHR). Nephrologists collaborate with pri-
mary care colleagues, helping primary care providers
manage the patients they can and refer those patients
who need specialist care. Our objective in this quality
improvement project was to assess the effect of PPNO
on CKD progression.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Setting
Kaiser Permanente Hawaii (KPHI) is one of eight regions
of Kaiser Permanente, one of the United States’ leading
health care providers and not-for-profit health plans
with 9.0 million members in nine states and the District
of Columbia. Kaiser Permanente addresses all health
care needs for adults and children, including preventive,
routine, specialty, emergency, and inpatient care, ancil-
lary testing, pharmacy and rehabilitative services, and
home care and functions as an accountable care organ-
ization [9]. KPHI has 224,000 members; 58 family prac-
tice physicians and 52 internists refer CKD patients to a
specialty division with six nephrologists. KPHI has an
integrated electronic health record (EHR), KP Health-
ConnectTM, providing comprehensive clinical informa-
tion on all members.
Population
Using the EHR, we identified all KPHI members during
2001–2010 who had at least two recorded serum cre-
atinine levels a minimum of three months apart identify-
ing different CKD stages and were at stage 3a CKD or
higher. From this dataset, we excluded patients with
serum creatinine patterns suggesting acute kidney injury:
a decline in function within 14 days of a previous cre-
atinine level followed by reversion to a previous higher
level within 90 days. Patients whose renal function
declined within 14 days of a previous creatinine level but
who did not recover function within 90 days were
included. In addition, we excluded those who had CKD
or needed renal replacement therapy before 2001 and
those whose CKD was diagnosed outside the KPHI sys-
tem. Over the entire time period, we identifed 25,881
members with at least one stage of CKD.
Proactive, population-based nephrologist oversight
In collaboration with primary care, nephrologists (B.L.
and A.L.) developed a model of proactive population-
based nephrology oversight (PPNO) for CKD patients.
The model addressed both patients without referrals
and those referred to nephrology by primary care physi-
cians (PCPs).
Patients without referrals
1. Using data extracted from the EHR, the population
management nephrologist (B. L.) generated
concise monthly individual profiles for all KPHI
patients with CKD, presented in risk-stratified
order. Stratification criteria included glomerular
filtration rate (GFR) and urine protein-to-creatinine
ratio. The nephrologists identified specific
laboratory criteria for patients at high risk ofprogression to ESRD: (1) GFR < 20 ml/min/
1.73 m2, (2) GFR < 40 ml/min/1.73 m2 and urine
protein-to-creatinine ratio > 2; or (3) urine
protein-to-creatinine ratio > 4. Laboratory criteria
for low risk status were GFR ≥ 30 ml/min/1.73 m2
and <1 gram proteinuria.
Weighting proteinuria equivalently with GFR in
determining risk status runs counter to stage based
management of CKD [10], but it was derived from
internal data analysis and is in agreement with
research [11-14]. An internal evidence-based
guidelines committee reviewed and adopted the
risk criteria and developed and distributed updated
CKD treatment guidelines to all PCPs to support
the quality improvement initiative [15].
2. Recognizing the impact of other factors, such as
age and comorbid conditions, on the potential
value of specialty care, the population management
nephrologist reviewed comprehensive clinical
information in the EHR for each high risk patient.
Using clinical judgment to determine which patients
would most benefit from nephrologist care, he
contacted the responsible PCPs and requested those
patients be referred for a nephrology visit.
3. For patients at low risk of progression, the
nephrologist proactively provided electronic
consultations to PCPs to improve CKD
management, again using comprehensive
information in the EHR. For example, the
nephrologist advised primary care providers
about maximal angiotensin-converting enzyme
inhibitor or angiotensin II receptor blocker
pharmacotherapy for patients with overt proteinuria
and uncontrolled blood pressure. Management
advice was sent to PCPs via KP HealthConnect
messaging. Pre-programmed blocks of text
minimized the time required to generate messages.
Referred patients
1. The population management nephrologist
comprehensively reviewed the EHR for all patients
referred for specialty care.
2. If the nephrologist judged the patient to be at
low risk, he contacted the referring physician
about the possibility of managing the patient in
the primary care setting with specific management
advice and the assurance that the patient would
be electronically monitored by the nephrologist.
3. To ensure patient safety and quality of care,
the population management nephrologist flagged
these patient records and looked at them first
when reviewing the monthly risk-stratified
profiles.
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nephrologist reviewed the profiles of the risk-stratified
CKD population, approximately 15 patients per week,
reviewing the KP HealthConnect record for additional
information as needed. Among the reviewed cases, many
patients benefitted from improved medical management,
but most did not immediately need a referral. Model-
identified consultations generated about 47 referrals per
year of high-risk patients. Nephrologists and primary
care providers collaboratively agreed to return about 25
low-risk referrals per year to primary care with active
nephrologist surveillance.
Design
We conducted a retrospective control analysis to quan-
tify the rate of CKD progression between stages before
and after the initiation of PPNO in 2005. We defined
the pre-PPNO period as January 1, 2001 to December
31, 2004 and the post-PPNO period as January 1, 2005
to December 31, 2008.
CKD staging, covariates, and data sources
We calculated an estimated GFR for each creatinine
level for all patients using the Modification of Diet
in Renal Disease Study equation, which incorporates
creatinine level, age, gender, and race or ethnicity [16].
We did not have race or ethnicity data, so our calcula-
tions underestimate the true GFR scores for African
Americans by a factor of 1.2. However, KP Hawaii has a
very small African American population (1.0%), and we
assumed this bias to be negligible. For patients with esti-
mated GFRs < 60 ml per minute per 1.73 m2, we identi-
fied the applicable stage of CKD using a modified
National Kidney Foundation classification of chronic
kidney disease: 45 to 59 ml per minute per 1.73 m2
(stage 3a), 30 to 44 ml per minute per 1.73 m2 (stage
3b), 15 to 29 ml per minute per 1.73 m2 (stage 4), and
less than 15 ml per minute per 1.73 m2 (stage 5) [17].
In addition, we identified patients receiving renal
replacement therapy as being in ESRD.
In addition to data on CKD stage, we included the fol-
lowing covariates: patient demographics (age, gender,
mortality), KP membership eligibility, diabetes, and
hypertension. We collected serum creatinine level,
patient demographics, and eligibility data from KP
HealthConnect from 2001 to 2008. We collected data on
diabetes and hypertension from Healthcare Employer Data
and Information Set (HEDIS) data from 2001 to 2008.
Statistical analysis
We used propensity score matching to control for
potential sampling bias in our assessment of the effect
of PPNO on the CKD population. For the entire pop-
ulation, we performed data cleaning and all statisticalanalyses using SAS 9.1 software. We pooled the data for
stages 4 and 5 to increase sample size. We summarized
the pre-matched population on the covariates for the
entire population.
We identified patients diagnosed with stage 3a CKD in
2001 and 2002 as the controls and followed their disease
progression for three years (2001 followed in 2001, 2002,
and 2003; 2002 followed in 2002, 2003, and 2004). We
identified patients diagnosed in 2005 and 2006 as the
cases and followed their disease progression for three
years (2005 followed in 2005, 2006, and 2007; 2006
followed in 2006, 2007, and 2008). Patients were identi-
fied by the year in which they had a first creatinine level
and subsequent level within 90 days that quantified
them as being in stage 3a, resulting in independent
samples. To account for transient fluctuations in renal
function, any change in estimated GFR sustained over
90 days was counted as progression.
We then matched control and case pairs, matching
randomly one-to-one without replacement for the pre-
and post- PPNO groups, based on propensity scoring for
age, gender, and the presence of diabetes and hyperten-
sion. We summarized the matched data on the covari-
ates and assessed the success of matching by examining
absolute differences between the covariate distribution
proportions in cases and controls.
Stage outcomes were observed for each matched indi-
vidual remaining in stage 3a or progressing from stage
3a to stages 3b, 4/5, and ESRD at one, two, and three
year intervals in the pre- and post-PPNO periods.
We tallied the final stage outcomes at the end of three
years. We tested the overall effect of the PPNO on
stage outcomes using the χ2-test. Within stages, we
converted the counts to proportions and assessed the
differences between the pre- and post-PPNO periods
with z-score tests.
The Kaiser Permanente Hawaii Institutional Review
Board approved the project.
Results
Analysis population
We identified 4,087 members at stage 3a in 2001 and
2002; 46% were male and 63% were 65 years of age or
older (Table 1). We identified 3,453 members at stage 3a
in 2005 and 2006; 46% were male and 59% were 65 years
of age or older.
Differences in CKD progression on matched data
We obtained 2,958 matches between the pre- and post-
PPNO data; the matches were well-balanced on the cov-
ariates (Table 1). During the pre-PPNO period, members
had an average of 8.52 serum creatinine levels recorded;
during the post-PPNO period, the comparable figure
was 9.07 (P= 0.049). The average first estimated GFR











Female 2,228 (54.5%) 1,875 (54.3%) 1,603 (54.2%) 1,608 (54.4%)
Age
0 - 19 1 (0.02%) 1 (0.03%) 1 (0.03%) 1 (0.03%)
20 - 44 223 (5.5%) 205 (5.9%) 182 (6.2%) 179 (6.1%)
45 - 64 1,276 (31.2%) 1,200 (34.8%) 965 (32.6%) 965 (32.6%)
≥ 65 2,587 (63.3%) 2,047 (59.3%) 1,810 (61.2%) 1,813 (61.3%)
Diabetes 844 (20.7%) 111 (3.2%) 111 (3.8%) 111 (3.8%)
Hypertension 1030 (25.2%) 683 (19.8%) 412 (13.9%) 415 (14.0%)
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period and 53.63 in the post-period; this difference was
not statistically significant (P= 0.052).
Stage outcomes for all individuals after three years
were tallied (Table 2). The progression within the post-
PPNO period was less severe and significantly different
from the pre-PPNO period (p = 0.027). Within stage 3a,
76 more individuals, or 2.6% of the match total,
remained in the post-period (95% confidence interval
[CI], 1.5% to 3.8%; P value < 0.00001). For stage 3b, 64
fewer individuals, or 2.2%, progressed from stage 3a to
stage 3b (95% CI, 0.7% to 3.6%; P value = 0.0017). Six
fewer individuals, or 0.20%, progressed from stage 3a to
stage 4/5 (95% CI, 0.0% to 0.87%; P value = 0.26). Seven
fewer individuals, or 0.24%, progressed from stage 3a to
ESRD (95% CI, 0.0% to 0.66%, P value = 0.10). There was
one more death, or 0.034%, in the post-period (95% CI,
0.0% to 1.19%; P value = 0.52).
Discussion
The overall effect of proactive population-based neph-
rologist oversight was statistically significant. The post-
PPNO period showed less severe progression. In particu-
lar, significantly more individuals remained in stage 3a
after three years. Progression from stage 3a to 3b was
significantly less in the post-period and marginally statis-
tically significantly less from stage 3a to ESRD. OurTable 2 CKD stage outcomes after three years among pre- an
as Stage 3a
Stages Pre-PPNO progression
Individuals (n = 2,958) Proportion Individu
3a 2,438 82%
3a to 3b 294 9.9%
3a to 4/5 49 1.7%
3a to ESRD 19 0.6%
Dead 158 5.3%finding that appropriate population care management
for patients with CKD slows the progression of disease
is consistent with other observational studies [18].
What our project adds to the literature is a model of
specialists providing population-based care that identi-
fies and risk stratifies the entire CKD population, direct-
ing nephrology resources to patients in need of them.
With enough information provided by the electronic
health record about individual cases, nephrologists can
determine which patients need referrals and which can
be managed by primary care physicians with nephrolo-
gist surveillance.
A similar model of systematic surveillance and shared
management by specialty and primary care also resulted
in slowed progression of disease [19]. However, our
population was defined by having CKD, not by having
received a referral for nephrology care. To the best of
our knowledge, our report is the first to detail the bene-
fits of population management by a specialty service of
all CKD patients—those who have been referred for
nephrologist care and those who have not.
Strengths of our report include the use of propensity
score matching to control for identified confounders
for which EHR data from 2001 to 2008 existed. These
included diabetes, which we identified using HEDIS
measures. HEDIS does not allow similar identification of
members with cardiovascular disease (CVD). However,d post-PPNO groups of individuals initially identified
Post-PPNO progression Difference
als (n = 2,958) Proportion Individuals Proportion
2,514 85% −76 2.6%
230 7.8% 64 2.2%
43 1.5% 6 0.20%
12 0.4% 7 0.24%
159 5.4% −1 0.034%
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reasonably assume that matching on diabetes status
eliminates some of the potential confounding introduced
by CVD status.
Members had more serum creatinine levels recorded
during the post-PPNO period than in the pre-period.
This is consistent with the goal of the program. In
addition, it provides a perspective on our analysis as
relatively conservative, since fewer levels during the pre-
period could reflect some undetected progression from
one stage to the next.
Several limitations deserve mention. Other factors may
have contributed to the effects we observed. Two confer-
ences in January 2005 and March 2007, sponsored by
the KPHI nephrology department and attended by
Kaiser Permanente and external physicians, focused on
improving the management of patients with CKD. In
addition, in June of 2007, an internal initiative was
undertaken to improve hypertension management
among patients with diabetes; chronic kidney disease is
associated with diabetes, hypertension, or both in more
than 90% of people with an estimated GFR below 60 ml
per minute per 1.73 m2 [21]. Finally, the use of panel
management in primary care, facilitated by the Panel
Support Tool, increased during the observation period
[22,23]. The latter two factors were reflected in substan-
tially improved HEDIS measures for calendar year 2007
(reported in 2008). Within the Medicare population, the
percentage of patients with diabetes whose blood pres-
sure was less than 140/90 mm Hg increased from 58.4%
to 72.0%; the percentage whose blood pressure was less

















3a to 3b 3a to 
Figure 1 Progression from stage 3a CKD at one to three years. The pe
are shown for one, two, and three years of follow up.We did not have comparable population data from the
pre- and post-PPNO periods for corollary measures, such
as angiotensin-converting enzyme inhibitor/angiotension
II receptor blocker use or blood pressure control. Such
data could provide more insight into the differences
in progression.
Our use of an retrospective control group was an add-
itional, albeit necessary, limitation to this evaluation.
Randomizing members into PPNO or usual care was
both inconsistent with the quality improvement nature
of this initiative and would have reduced our ability to
make statistical inferences, given the small population
that progressed from stage 3a to a later stage of CKD. In
addition, the Hawaii population is distinguished by a
higher proportion of members of Asian/Pacific Islander
origin, precluding the use of a control group from an-
other region. We also limited the post-period to 2008 to
have a balanced population with the pre-period.
Our population included only members with serial
recorded serum creatinine levels; reduced GFR is
undetected in a substantial minority of individuals with
CKD [24]. Bias may have been introduced when PCPs
selected patients for renal function testing. Our follow-
up period of three years was likely too short to fully
capture the effect of PPNO. The few existing reports of
the natural history of CKD suggest that three years is a
minimum follow-up period [25,26]. Figure 1 suggests an
increasing effect with longer follow-up, although further
assessment is needed to confirm this. Additionally, the
lack of statistically significant decrease in progression
from stage 3a to stage 4/5 may be due to sample size
and to the decreasing slope of progression in the lateryear 
4/5 3a to ESRD 
rcent of patients progressing from stage 3a to stage 3b, 4/5, and ESRD
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of diabetes in the pre- and post-PPNO populations were
not optimal, but the impact was limited by the use of a
more rigorous propensity score matching methodology.
Proactive population-based nephrologist care requires
comprehensive health information technology. Our
model of care is an example of its meaningful use to im-
prove patient outcomes, in keeping with the spirit of the
Health Information Technology for Economic and Clin-
ical Health (HITECH) Act of 2009 [28]. In addition
to generating a list of patients with CKD, which is an
objective in the menu set of the final regulation, we used
health information technology to risk stratify the popula-
tion, communicate with primary care physicians, and
review and record complete clinical information [29].
Our model of care provides additional evidence support-
ing the federal government’s investment in health infor-
mation technology as a lever for improving health care
quality and efficiency.
However, health information technology alone is insuf-
ficient to create change of the magnitude we observed.
It is important to note that organization-wide goals
and financial incentives are aligned throughout Kaiser
Permanente, as an example of an accountable care
organization, to provide efficient and effective care and
to consider the larger health trajectory of the patient;
neither nephrologists nor primary care physicians are
penalized or rewarded for shifts in the volume of visits.
Risk stratification allows specialists to address all CKD
patients regardless of referral status. This approach can
potentially be applied to other chronic conditions in
which at least one key metric related to quality of care is
available. For instance, pain management specialists
might use the number of dispensed opiate prescriptions
to identify chronic pain patients with unmet needs, and
cardiologists could use the ejection fraction to risk strat-
ify the population of patients with congestive heart fail-
ure. Future research is needed to confirm this.
Future research is also needed to evaluate the cost-
effectiveness of this approach. We estimated that
approximately $8 million in RRT costs were avoided
between 2005 and 2008 by the reduced progression to
ESRD but did not take into account any other factors.
The reduced progression from stage 3a to stage 3b may
have no effect on RRT rates or mortality.
Conclusions
Proactive, population-based nephrologist oversight was
associated with a statistically significant decrease in
progression. In accountable care settings with enabling
comprehensive health information technology and aligned
incentives, risk stratification and targeted proactive inter-
vention can achieve population-level care improvements
in chronic kidney disease. In the face of expandingdemand for care under U.S. health care reform, our
model provides evidence that health information technol-
ogy can help leverage existing resources to provide better
care for more people.
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